

**Hang Seng Investment Series
(the “Series”)**

Notice to Unitholders

This document is important and requires your immediate attention. If you are in doubt about the contents of this document, you should seek independent professional advice.

Capitalized terms used herein but not otherwise defined will have the same meanings as defined in the Explanatory Memorandum of the Series.

Investors should note that all investments involve risks (including the possibility of loss of the capital invested), prices of fund units may go up as well as down and past performance is not indicative of future performance. Investors should read the relevant Fund’s offering documents (including the full text of the risk factors stated therein) in detail before making any investment decision.

SFC authorisation is not a recommendation or endorsement of the Fund nor does it guarantee the commercial merits of the Fund or its performance. It does not mean the Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

Dear Unitholders

Amendment to the Explanatory Memorandum of the Series

We, as the Manager of the Series, are writing to inform you that with effect from the date of this document, an amendment has been made to the Explanatory Memorandum of the Series to reflect updates to prohibited securities related risk disclosure. Please refer to the “Amendment to the Explanatory Memorandum of the Series” for details.

For the avoidance of doubt: (i) the amendment outlined in this document does not amount to a material change to the fund(s) in the Series; (ii) there will be no material change or increase in the overall risk profile of the fund(s) in the Series as a result of the amendment outlined in this document; and (iii) the amendment outlined in this document does not have any material adverse impact on the rights or interests of the Unitholders of the fund(s) in the Series.

If you have any queries concerning the above, please contact us at (852) 2198 5890 during office hours.

We accept full responsibility for the accuracy of the contents of this document as at the date of its publication.

Hang Seng Investment Management Limited
31 January 2024

**Hang Seng Investment Series
(the “Series”)**

This document is important and requires your immediate attention. If you are in doubt about the contents of this document, you should seek independent professional advice.

Investors should note that all investments involve risks (including the possibility of loss of the capital invested), prices of fund units may go up as well as down and past performance is not indicative of future performance. Investors should read the relevant Fund’s offering documents (including the full text of the risk factors stated therein) in detail before making any investment decision.

SFC authorisation is not a recommendation or endorsement of the Fund nor does it guarantee the commercial merits of the Fund or its performance. It does not mean the Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

Amendment to the Explanatory Memorandum of the Series

The following amendment has been made to the Explanatory Memorandum of the Series with effect from the date of this document. This amendment forms part of and should be read in conjunction with the Explanatory Memorandum of the Series.

RISK FACTORS

The last risk factor under the sub-section headed “**General Risks**” has been deleted in its entirety and replaced by the following:

“*Prohibited securities risks*”

In accordance with HSBC Group policy (which applies as the Manager is a member of the HSBC Group), a Fund may not invest in the securities of companies considered to be involved directly in the use, development, manufacturing, stockpiling, transfer or trade of controversial weapons banned by international convention. As this policy aims to prohibit investment in certain types of securities, investors should be aware that this reduces the investment universe and prevents a Fund from benefitting from any potential returns from these companies (in case there is originally no such restriction at the fund or index level). This policy does not apply to third party funds or derivative instruments any Fund may invest in.”

If you have any queries concerning the above, please contact us at (852) 2198 5890 during office hours.

We accept full responsibility for the accuracy of the contents of this document as at the date of its publication.

Hang Seng Investment Management Limited
31 January 2024

恒生精選基金系列
(「基金系列」)

單位持有人通告

此乃重要文件，務請閣下即時垂注。閣下如對本文件之內容有任何疑問，應尋求獨立及專業的意見。

如沒有特別說明，本文件中所用詞彙與基金系列的基金說明書所定義的有著相同涵義。

投資者須注意，所有投資均涉及風險（包括可能會損失投資本金），基金單位價格可升亦可跌，過往表現並不可作為日後表現的指引。投資者在作出任何投資決定前，應詳細閱讀有關基金之銷售文件（包括當中所載之風險因素之全文）。

證監會認可不等如對基金作出推介或認許，亦不是對基金的商業利弊或表現作出保證，更不代表基金適合所有投資者，或認許基金適合任何個別投資者或任何類別的投資者。

致各單位持有人

基金系列的基金說明書之修訂

我們作為基金系列之基金經理，現通知閣下，基金系列的基金說明書由本文件刊發日起已作出修訂，以反映受禁證券相關風險披露的更新。詳情請參閱隨附的「基金系列的基金說明書之修訂」。

為免生疑問：(i)本文件所列修訂不構成基金系列內的基金的重大變動；(ii)基金系列內的基金之總體風險狀況不會因本文件所列修訂而產生重大變化或有所增加；及(iii)本文件所列修訂對基金系列內的基金的單位持有人的權利或利益並無任何重大不利影響。

倘若閣下對上述事宜有任何疑問，請於辦公時間內致電(852) 2198 5890 與我們聯絡。

我們對本文件所載資料於其刊發日之準確性承擔全部責任。

恒生投資管理有限公司

2024年1月31日

恒生精選基金系列
(「基金系列」)

此乃重要文件，務請閣下即時垂注。閣下如對本文件之內容有任何疑問，應尋求獨立及專業的意見。

投資者須注意，所有投資均涉及風險（包括可能會損失投資本金），基金單位價格可升亦可跌，過往表現並不可作為日後表現的指引。投資者在作出任何投資決定前，應詳細閱讀有關基金之銷售文件（包括當中所載之風險因素之全文）。

證監會認可不等如對基金作出推介或認許，亦不是對基金的商業利弊或表現作出保證，更不代表基金適合所有投資者，或認許基金適合任何個別投資者或任何類別的投資者。

基金系列的基金說明書之修訂

基金系列的基金說明書由本文件刊發日起已作出以下修訂。此修訂構成基金系列的基金說明書的一部分，並應與基金系列的基金說明書一併閱讀。

風險因素

於分節標題為「**一般風險**」下的最後一個風險因素已被全部刪去並由以下取代：

「受禁證券風險

按照滙豐集團政策（因基金經理為滙豐集團的成員而適用），子基金或不會投資於被視為直接涉及使用、發展、製造、存儲、轉讓或銷售國際公約禁止的具爭議武器的公司證券。由於此政策旨在禁止投資於若干類型證券，投資者應注意，這會減少投資範疇並阻礙子基金從該等公司的任何潛在回報中受惠（如果在基金或指數層面原本沒有此類限制）。此政策不適用於任何子基金投資的第三方基金或衍生工具。」

倘若閣下對上述事宜有任何疑問，請於辦公時間內致電(852) 2198 5890 與我們聯絡。

我們對本文件所載資料於其刊發日之準確性承擔全部責任。

恒生投資管理有限公司

2024年1月31日